IHT Wealth Management LLC lifted its position in shares of AstraZeneca plc (NYSE:AZN) by 9.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,754 shares of the company’s stock after buying an additional 1,235 shares during the quarter. IHT Wealth Management LLC’s holdings in AstraZeneca were worth $522,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Berman Capital Advisors LLC bought a new position in shares of AstraZeneca in the fourth quarter valued at $38,000. Sontag Advisory LLC bought a new position in shares of AstraZeneca in the fourth quarter valued at $40,000. Portfolio Solutions LLC bought a new position in shares of AstraZeneca in the fourth quarter valued at $40,000. CNB Bank lifted its position in shares of AstraZeneca by 245.0% during the fourth quarter. CNB Bank now owns 1,080 shares of the company’s stock valued at $41,000 after purchasing an additional 767 shares in the last quarter. Finally, Loeb Partners Corp bought a new position in shares of AstraZeneca during the fourth quarter valued at about $46,000. Institutional investors own 18.31% of the company’s stock.
AstraZeneca stock traded up $0.29 during mid-day trading on Monday, hitting $39.81. 3,006,000 shares of the company traded hands, compared to its average volume of 5,577,003. The company has a debt-to-equity ratio of 1.24, a current ratio of 0.96 and a quick ratio of 0.78. AstraZeneca plc has a one year low of $34.38 and a one year high of $43.29. The firm has a market cap of $100.78 billion, a PE ratio of 11.51, a PEG ratio of 1.16 and a beta of 0.51.
AstraZeneca (NYSE:AZN) last issued its earnings results on Thursday, February 14th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $0.73 by $0.85. AstraZeneca had a net margin of 9.76% and a return on equity of 32.47%. The company had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.33 billion. During the same period in the previous year, the firm earned $1.30 earnings per share. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. As a group, research analysts anticipate that AstraZeneca plc will post 1.79 earnings per share for the current year.
The company also recently announced a semiannual dividend, which was paid on Wednesday, March 27th. Investors of record on Friday, March 1st were paid a $0.95 dividend. This represents a dividend yield of 4.64%. This is an increase from AstraZeneca’s previous semiannual dividend of $0.45. The ex-dividend date of this dividend was Thursday, February 28th. AstraZeneca’s payout ratio is presently 53.76%.
A number of research firms recently weighed in on AZN. Cowen raised shares of AstraZeneca from a “market perform” rating to an “outperform” rating and raised their price target for the company from $42.00 to $48.00 in a research report on Monday, April 1st. ValuEngine lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. UBS Group lowered shares of AstraZeneca from a “neutral” rating to a “sell” rating and set a $40.73 price target on the stock. in a research report on Tuesday, April 2nd. Goldman Sachs Group reissued a “sell” rating on shares of AstraZeneca in a research report on Tuesday, February 26th. Finally, Zacks Investment Research lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Tuesday, January 29th. Three analysts have rated the stock with a sell rating, five have given a hold rating and eleven have assigned a buy rating to the company. AstraZeneca currently has a consensus rating of “Hold” and a consensus price target of $45.46.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Gross Domestic Product (GDP)
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.